Lilly Sets Up First China Venture Fund
This article was originally published in PharmAsia News
Executive Summary
After its initial investment in BioVeda China, Eli Lilly Asia Capital Fund is set to enter the second phase of directly investing in the pharmaceutical sector. According to officials, the fund, which targets China as a major investment market, is focusing on life sciences, medical and diagnostic devices, and health care. Project collaboration with universities and academic institutions in key coastal cities will get an initial injection of $1-5 million and up to a total of $10-15 million each. GSK is considering setting up its own venture capital in China if suitable projects are available. (Click here for more - Chinese Language)